Insulin versus a combination of insulin and sulfonylurea in the treatment of NIDDM patients with secondary oral failure

Diabetes Research and Clinical Practice

Volumn 30, Issue 1, 1995, Pages 27-35

  Ravnik Oblak, Maja ^a   Mrevlje, Franc ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Combined therapy; NIDDM; Secondary drug failure

Indexed keywords

C PEPTIDE; GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GLUCOSE CLAMP TECHNIQUE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; MIDDLE AGED; SULFONYLUREA COMPOUNDS; TIME FACTORS; TREATMENT FAILURE;

EID: 0029584337     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/0168-8227(95)01137-4     Document Type: Article

References (36)

1. Favourable effect of supplemental Orinase in insulin-treated labile diabetics
2. Physiological basis of the effectiveness of combined insulin-tolbutamide
3. Assessment of insulin resistance with the insulin suppression test and the euglycemic clamp
4. The physiologic action of insulin on glucose uptake and its relevance to the interpretation of the metabolic clearance rate of glucose
5. Kombinations-therapie Insulin/Glibenclamid bei Typ-II-Diabetikern mit relativer Insulin-resistenz
6. Addition of sulfonylurea to insulin treatment in poorly conrolled type II diabetes. A double-blind, randomized clinical trial
7. The combination of insulin and sulphonylurea in the treatment of secondary drug failure in patients with type II diabetes
8. Kombinierte Behandlung von Typ-II-Diabetikern mit Insulin und Glibenclamid nach Tablettensekundärversagen
9. Kombination von Insulin und Sulfonylharnstoffen bei der Therapie des Diabetes mellitus vom Erwachsenen-Typ
10. Insulin versus insulin plus sulfonylureas in type 2 diabetic patients with secondary drug failure to sulfonylureas
11. Insulin and sulfonylurea agent in non-insulin-dependent diabetes mellitus
12. The combined use of insulin and sulfonylurea therapy in patients with non-insulin-dependent diabetes mellitus
13. Glyburide decreases insulin requirement, increases beta cell response to mixed meal, and does not affect insulin sensitivity: effects of short and long-term combined treatment in secondary failure to sulfonylurea
14. Glibenclamide-insulin in combination in the management of secondary failure of sulfonylurea medication
15. Sulfonylurea failure in Type 2 diabetes: treatment with a basal insulin supplement
16. Effect of glyburide on glycemic control, insulin requirement, and glucose metabolism in insulin-treated diabetic patients
17. Insulin-glyburide combination therapy for non-insulin-dependent diabetes mellitus: a long-term double-blind, placebo-controlled trial
18. What causes hyperglycemia in non-insulin dependent diabetes mellitus
19. Die Kombinationstherapie Insulin/Sulfonylharnstoff in der Langzeittherapie des typ-II-Diabetes nach Sekundaerversagen
20. Sulphonylurea/insulin combination in Diabetes mellitus following secondary failure to tablets
21. Combined insulin and sulfonylurea therapy for type 2 diabetes mellitus
22. Partial recovery of insulin secretion and action after combined insulin-sulfonylurea treatment in Type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral agents
23. Blood glucose control and insulin secretion improved with combined therapy in type 2 diabetic patients with secondary failure to oral hypoglycaemic agents
24. Insulin/sulfonylurea combinations: a new beginning?
25. Investigation of the mechanism of action of glibenclamide and insulin administered in combination in type-II diabetic patients with secondary failue of oral treatment
26. Long-term results of combined insulin/sulphonylurea therapy: results, critical assessment, clinical consequences
27. Natural history of beta cell dysfunction in NIDDM
28. The triumvirate: beta cell, muscle, liver. Lilly lecture 1987
29. Transient effect of the combination of insulin and sulfonylurea (glibenclamide) on glycemic control in non-insulin dependent diabetes poorly controlled with insulin alone
30. Combined treatment of type-II diabetic patients with insulin and glibenclamide after secondary failure to tablets
31. Morning or bedtime NPH insulin combined with sulfonylurea in treatment of NIDDM
32. Comparison of preprandial administration of regular insulin with administration of NPH insulin at bed time and of conventional insulin therapy in combination therapy with insulin/sulfonylurea in type-II diabetes
33. Combination therapy with different doses of glibenclamide
34. Long-term results of combined insulin/sulphonylurea therapy: results, critical assessment, clinical consequences
35. Combination insulin-sulfonylurea therapy
36. Combination therapy with insulin and sulfonylurea for type II diabetes